NEW YORK, NY / ACCESSWIRE / January 14, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Splunk Inc. (NASDAQ:SPLK)
Class Period: October 21, 2020 - December 2, 2020
Lead Plaintiff Deadline: February 2, 2021
The SPLK lawsuit alleges that throughout the class period, Splunk Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in SPLK: http://www.kleinstocklaw.com/pslra-1/splunk-inc-loss-submission-form?id=12164&from=1
Minerva Neurosciences, Inc. (NASDAQ:NERV)
Class Period: May 15, 2017 - November 30, 2020
Lead Plaintiff Deadline: February 8, 2021
The NERV lawsuit alleges Minerva Neurosciences, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in NERV: http://www.kleinstocklaw.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?id=12164&from=1
Triterras, Inc., f/k/a Netfin Acquisition Corp. (NASDAQ:TRIT)
Class Period: August 20, 2020 - December 16, 2020
Lead Plaintiff Deadline: February 19, 2021
Triterras, Inc., f/k/a Netfin Acquisition Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the extent to which Company's revenue growth relied on Triterras' relationship with Rhodium to refer users to the Kratos platform; (2) that Rhodium faced significant financial liabilities that jeopardized its ability to continue as a going concern; (3) that, as a result, Rhodium was likely to refer fewer users to the Company's Kratos platform; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in TRIT: http://www.kleinstocklaw.com/pslra-1/triterras-inc-f-k-a-netfin-acquisition-corp-loss-submission-form?id=12164&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
SOURCE: The Klein Law Firm
View source version on accesswire.com: